INFARMED - AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DA SAUDE IP

Their core work

INFARMED is Portugal's national medicines and health products authority — the regulatory body responsible for evaluating, authorizing, and supervising pharmaceuticals and medical devices in the Portuguese market. Within H2020, they contribute regulatory expertise to European initiatives on drug identification standards, cross-border eHealth systems, and translational medicine infrastructure. Their participation brings the perspective of a national regulator to multi-country efforts aimed at harmonizing medicine data, pharmacovigilance, and regulatory science training across Europe.

What they specialise in

How they've shifted over time

With only three projects clustered between 2019 and 2020, the evolution window is narrow. Early keywords point to foundational regulatory science (STARS, started 2019), while subsequent projects expanded into applied digital health infrastructure — medicine identification standards (UNICOM) and translational research platforms (EATRIS-Plus). The shift suggests a move from building internal regulatory capacity toward contributing regulatory authority to pan-European digital health and precision medicine ecosystems.

INFARMED is positioning itself as a regulatory voice within European digital health infrastructure and medicine data harmonization efforts, making them a relevant partner for projects requiring national authority engagement.

How they like to work

INFARMED participates exclusively as a partner — never as coordinator — which is consistent with their role as a national regulatory authority contributing domain expertise rather than leading research. With 74 unique partners across 26 countries from just 3 projects, they operate in large, pan-European consortia typical of coordination and support actions. This means they are experienced in multi-country regulatory collaboration but unlikely to drive the scientific agenda themselves.

Despite only three projects, INFARMED has touched 74 partners across 26 countries, reflecting participation in large EU-wide consortia. Their network is broad and pan-European rather than concentrated in any single region.

What sets them apart

INFARMED brings something most academic or industrial partners cannot: the authority and perspective of a national medicines regulator. For any consortium that needs regulatory buy-in, policy alignment, or real-world validation of pharmaceutical standards within a member state, INFARMED is a credible and institutionally embedded partner. Their involvement signals regulatory relevance to evaluators and adds weight to proposals touching drug authorization, pharmacovigilance, or health data standards.

Highlights from their portfolio

• UNICOM
  Largest project by funding (EUR 358,750), focused on scaling universal medicine identification — directly relevant to EU-wide pharmaceutical data interoperability.
• EATRIS-Plus
  Connects INFARMED to the EATRIS-ERIC research infrastructure for personalised medicine, bridging regulatory authority with translational research capacity.